Results 81 to 90 of about 49,117 (237)
Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies [PDF]
, 2012 The immunoglobulin (Ig) protein domain is widespread in nature having a well-recognized role in proteins of the immune system. In this review, we describe the proteins containing Ig-like domains in Escherichia coli and entero-bacteria, reporting their ...
Bluhm, Hendrik +3 more
core +2 more sources
Acta Physiologica, Volume 242, Issue 6, June 2026.ABSTRACT Aim Myocardial infarction (MI) is one of the leading causes of death worldwide. MI is associated with cardiac structural and functional alterations. Among these, cardiac fibrosis may be significantly influenced by mitochondrial dysfunction. We sought to evaluate whether the injection of functional mitochondria from healthy muscle could improve
María Cuesta‐Corral +13 more
wiley +1 more source
VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins [PDF]
, 2015 Peer reviewedPublisher ...
Clem +4 more
core +3 more sources
FEBS Open Bio, Volume 16, Issue 5, Page 1030-1043, May 2026.Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source
Non-specific binding of antibodies in immunohistochemistry: Fakes and facts [PDF]
, 2011 Protocols for blocking non-specific antibody (Ab) binding in immunohistochemistry are based on rather contradictory and outdated reports. This prompted us to prove, whether non-specific Ab binding may really lead to unwanted background staining in ...
Igor Buchwalow +3 more
core +1 more source
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]
, 2017 Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena +3 more
core +1 more source
Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein
Chemistry–Methods, Volume 6, Issue 5, May 2026.The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley +4 more
wiley +1 more source
Model for the Interaction of T-cell Receptors with Peptide/MHC Complexes [PDF]
, 1989 The immune response against a viral infection is mediated by two different types of cells known as B and T lymphocytes. The receptor on the B cell is the well-characterized antibody molecule, which exists in a membrane-bound form and in a secreted form ...
Bjorkman, P. J., Davis, M. M.
core +1 more source
Structural Determination of a Human IgE Epitope on Major Birch Allergen Bet v 1
Allergy, EarlyView.
Andrea O'Malley +4 more
wiley +1 more source
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr +4 more
wiley +1 more source